23.72 USD
-0.56 (-2.31%)
24.11 USD
+0.39 (+1.64%)
Overall GLUE gets a fundamental rating of 5 out of 10. We evaluated GLUE against 528 industry peers in the Biotechnology industry. While GLUE has a great health rating, its profitability is only average at the moment. GLUE has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year GLUE was profitable.
In the past year GLUE had a positive cash flow from operations.
GLUE had negative earnings in each of the past 5 years.
GLUE had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of GLUE (4.56%) is better than 90.91% of its industry peers.
GLUE has a better Return On Equity (8.52%) than 91.86% of its industry peers.
The Return On Invested Capital of GLUE (1.69%) is better than 89.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.56% | ||
| ROE | 8.52% | ||
| ROIC | 1.69% |
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GLUE has a Profit Margin of 11.54%. This is amongst the best in the industry. GLUE outperforms 91.48% of its industry peers.
With an excellent Operating Margin value of 4.69%, GLUE belongs to the best of the industry, outperforming 89.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.69% | ||
| PM (TTM) | 11.54% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), GLUE is destroying value.
Compared to 1 year ago, GLUE has more shares outstanding
The number of shares outstanding for GLUE has been increased compared to 5 years ago.
There is no outstanding debt for GLUE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
GLUE has an Altman-Z score of 4.36. This indicates that GLUE is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.36, GLUE is doing good in the industry, outperforming 71.97% of the companies in the same industry.
GLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.36 |
ROIC/WACC0.19
WACC8.82%
2.3 Liquidity
GLUE has a Current Ratio of 6.54. This indicates that GLUE is financially healthy and has no problem in meeting its short term obligations.
GLUE's Current ratio of 6.54 is fine compared to the rest of the industry. GLUE outperforms 67.05% of its industry peers.
A Quick Ratio of 6.54 indicates that GLUE has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.54, GLUE is in the better half of the industry, outperforming 67.80% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.54 | ||
| Quick Ratio | 6.54 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 116.94% over the past year.
The Revenue has grown by 1112.27% in the past year. This is a very strong growth!
EPS 1Y (TTM)116.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.79%
Revenue 1Y (TTM)1112.27%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%38.54%
3.2 Future
The Earnings Per Share is expected to decrease by -9.22% on average over the next years.
The Revenue is expected to grow by 22.59% on average over the next years. This is a very strong growth
EPS Next Y72.28%
EPS Next 2Y-18.02%
EPS Next 3Y-10.72%
EPS Next 5Y-9.22%
Revenue Next Year431.8%
Revenue Next 2Y47.38%
Revenue Next 3Y36.35%
Revenue Next 5Y22.59%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 76.52 indicates a quite expensive valuation of GLUE.
GLUE's Price/Earnings ratio is rather cheap when compared to the industry. GLUE is cheaper than 89.96% of the companies in the same industry.
GLUE is valuated expensively when we compare the Price/Earnings ratio to 27.25, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for GLUE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 76.52 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GLUE indicates a rather cheap valuation: GLUE is cheaper than 90.72% of the companies listed in the same industry.
98.48% of the companies in the same industry are more expensive than GLUE, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.65 | ||
| EV/EBITDA | 57.63 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
GLUE's earnings are expected to decrease with -10.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)1.06
PEG (5Y)N/A
EPS Next 2Y-18.02%
EPS Next 3Y-10.72%
5. Dividend
5.1 Amount
GLUE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
23.72
-0.56 (-2.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.54%
Inst Owner Change0.04%
Ins Owners0.81%
Ins Owner Change1.5%
Market Cap1.54B
Revenue(TTM)181.54M
Net Income(TTM)20.95M
Analysts85.33
Price Target21.78 (-8.18%)
Short Float %10.84%
Short Ratio6.55
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.53%
Min EPS beat(2)13.2%
Max EPS beat(2)61.87%
EPS beat(4)4
Avg EPS beat(4)354.59%
Min EPS beat(4)13.2%
Max EPS beat(4)1080.39%
EPS beat(8)7
Avg EPS beat(8)177.66%
EPS beat(12)11
Avg EPS beat(12)119.51%
EPS beat(16)13
Avg EPS beat(16)84.82%
Revenue beat(2)2
Avg Revenue beat(2)120.76%
Min Revenue beat(2)110.55%
Max Revenue beat(2)130.97%
Revenue beat(4)4
Avg Revenue beat(4)277.19%
Min Revenue beat(4)110.55%
Max Revenue beat(4)444.91%
Revenue beat(8)6
Avg Revenue beat(8)183.66%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)22.54%
PT rev (3m)27.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-232.4%
EPS NY rev (1m)2.92%
EPS NY rev (3m)-43.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-48.98%
Revenue NY rev (1m)1.38%
Revenue NY rev (3m)3.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 76.52 | ||
| Fwd PE | N/A | ||
| P/S | 8.51 | ||
| P/FCF | 10.65 | ||
| P/OCF | 10.36 | ||
| P/B | 6.28 | ||
| P/tB | 6.28 | ||
| EV/EBITDA | 57.63 |
EPS(TTM)0.31
EY1.31%
EPS(NY)-1.42
Fwd EYN/A
FCF(TTM)2.23
FCFY9.39%
OCF(TTM)2.29
OCFY9.66%
SpS2.79
BVpS3.78
TBVpS3.78
PEG (NY)1.06
PEG (5Y)N/A
Graham Number5.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.56% | ||
| ROE | 8.52% | ||
| ROCE | 2.14% | ||
| ROIC | 1.69% | ||
| ROICexc | 94.17% | ||
| ROICexgc | 94.17% | ||
| OM | 4.69% | ||
| PM (TTM) | 11.54% | ||
| GM | N/A | ||
| FCFM | 79.89% |
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 49.42% | ||
| Cap/Sales | 2.27% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 885.62% | ||
| Profit Quality | 692.36% | ||
| Current Ratio | 6.54 | ||
| Quick Ratio | 6.54 | ||
| Altman-Z | 4.36 |
F-Score8
WACC8.82%
ROIC/WACC0.19
Cap/Depr(3y)233.13%
Cap/Depr(5y)356.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)116.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.79%
EPS Next Y72.28%
EPS Next 2Y-18.02%
EPS Next 3Y-10.72%
EPS Next 5Y-9.22%
Revenue 1Y (TTM)1112.27%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%38.54%
Revenue Next Year431.8%
Revenue Next 2Y47.38%
Revenue Next 3Y36.35%
Revenue Next 5Y22.59%
EBIT growth 1Y106.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.16%
EBIT Next 3Y42.19%
EBIT Next 5YN/A
FCF growth 1Y218.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y253.12%
OCF growth 3YN/A
OCF growth 5YN/A
MONTE ROSA THERAPEUTICS INC / GLUE FAQ
Can you provide the ChartMill fundamental rating for MONTE ROSA THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 5 / 10 to GLUE.
What is the valuation status of MONTE ROSA THERAPEUTICS INC (GLUE) stock?
ChartMill assigns a valuation rating of 4 / 10 to MONTE ROSA THERAPEUTICS INC (GLUE). This can be considered as Fairly Valued.
What is the profitability of GLUE stock?
MONTE ROSA THERAPEUTICS INC (GLUE) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for GLUE stock?
The Price/Earnings (PE) ratio for MONTE ROSA THERAPEUTICS INC (GLUE) is 76.52 and the Price/Book (PB) ratio is 6.28.
Can you provide the financial health for GLUE stock?
The financial health rating of MONTE ROSA THERAPEUTICS INC (GLUE) is 8 / 10.